Brokerages Set Coherus Oncology, Inc. (NASDAQ:CHRS) Target Price at $4.02

Coherus Oncology, Inc. (NASDAQ:CHRS) has earned a consensus rating of “Hold” from the five research firms that are currently covering the stock, Marketbeat.com reports. One equities research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and three have issued a buy recommendation on the company. The average 12 month price target among brokerages that have updated their coverage on the stock in the last year is $5.5125.

A number of equities analysts recently weighed in on the stock. Weiss Ratings reissued a “sell (d)” rating on shares of Coherus Oncology in a report on Wednesday, October 8th. Oppenheimer began coverage on shares of Coherus Oncology in a research note on Thursday. They issued an “outperform” rating and a $10.00 target price on the stock. Finally, Wall Street Zen upgraded shares of Coherus Oncology from a “sell” rating to a “hold” rating in a research note on Saturday, November 8th.

Hedge Funds Weigh In On Coherus Oncology

A number of large investors have recently made changes to their positions in CHRS. Quarry LP purchased a new position in shares of Coherus Oncology during the third quarter worth about $26,000. Voya Investment Management LLC purchased a new position in Coherus Oncology in the 3rd quarter worth approximately $28,000. International Assets Investment Management LLC bought a new position in shares of Coherus Oncology in the 2nd quarter worth $33,000. Corient Private Wealth LLC increased its holdings in shares of Coherus Oncology by 20.0% in the 2nd quarter. Corient Private Wealth LLC now owns 60,000 shares of the biotechnology company’s stock worth $44,000 after buying an additional 10,000 shares during the last quarter. Finally, BNP Paribas Financial Markets raised its position in shares of Coherus Oncology by 108.2% during the 3rd quarter. BNP Paribas Financial Markets now owns 26,620 shares of the biotechnology company’s stock valued at $44,000 after buying an additional 13,832 shares in the last quarter. 72.82% of the stock is owned by institutional investors.

Coherus Oncology Trading Up 29.6%

CHRS opened at $2.06 on Thursday. The company has a fifty day moving average price of $1.39 and a two-hundred day moving average price of $1.34. Coherus Oncology has a 1-year low of $0.71 and a 1-year high of $2.17. The company has a market cap of $248.99 million, a P/E ratio of 1.55 and a beta of 0.96. The company has a current ratio of 1.24, a quick ratio of 1.23 and a debt-to-equity ratio of 0.42.

Coherus Oncology (NASDAQ:CHRS) last issued its earnings results on Thursday, November 6th. The biotechnology company reported ($0.33) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.34) by $0.01. The firm had revenue of $11.57 million for the quarter, compared to analyst estimates of $13.41 million. Analysts predict that Coherus Oncology will post -1.05 EPS for the current fiscal year.

Coherus Oncology Company Profile

Coherus Oncology, Inc is a commercial-stage biopharmaceutical company focused on the development, manufacturing and commercialization of biologic therapies for oncology support and immuno-oncology. Founded in 2010 and headquartered in Redwood City, California, Coherus specializes in biosimilar versions of established oncology agents as well as novel immunotherapy candidates.

The company’s lead marketed products include Udenyca (pegfilgrastim-cbqv) and Fulphila (pegfilgrastim-jmdb), biosimilars to Amgen’s Neulasta, which are designed to reduce the incidence of infection in patients undergoing myelosuppressive chemotherapy.